JAK2 and neoplasm: In vivo experiments have shown that JAK2-mutant hematopoietic cells displayed metabolic alterations essential for the pathogenesis of these neoplasms, leading to hypoglycemia, adipose tissue atrophy and early mortality [130] that could be reversed in the murine model using 3-(3-pyridinyl)-1-(4pyridinyl)-2-propen-1-one, which inhibits Pfkfb3, a key regulator of glycolysis.